Our goal is to continue to discover cellular and molecular mechanisms of activity-dependent circuit remodeling that optimize behavioral performance, and to reveal the FMRP-dependent neurodevelopmental processes that go awry in FXS, so as to be able to devise effective new treatments for this devastating disease state. This evidence concerns the gene FMR1 and fragile X syndrome.